INHIBITORY EFFECTS OF SUBSTRATE-BASED BCR-ABL1 KINASE INHIBITORS ON THE GROWTH OF CHRONIC MYELOID LEUKEMIA CELL LINE K562

被引：0

作者：

Huang, Y. -H. ^{[1
]}

Henriques, S. Troeira ^{[1
]}

Lawrence, N. ^{[1
]}

Kaas, Q. ^{[1
]}

Craik, D. J. ^{[1
]}

机构：

[1] Univ Queensland, Inst Mol Biosci, Brisbane, Qld, Australia

来源：

JOURNAL OF PEPTIDE SCIENCE | 2016年 / 22卷

关键词：

D O I：

暂无

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

PP IX-257

引用

页码：S174 / S174

页数：1

共 50 条

[21] β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia [J].

Eiring, A. M. ;

Khorashad, J. S. ;

Anderson, D. J. ;

Yu, F. ;

Redwine, H. M. ;

Mason, C. C. ;

Reynolds, K. R. ;

Clair, P. M. ;

Gantz, K. C. ;

Zhang, T. Y. ;

Pomicter, A. D. ;

Kraft, I. L. ;

Bowler, A. D. ;

Johnson, K. ;

Mac Partlin, M. ;

O'Hare, T. ;

Deininger, M. W. .

LEUKEMIA, 2015, 29 (12) :2328-2337

[22] β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia [J].

A M Eiring ;

J S Khorashad ;

D J Anderson ;

F Yu ;

H M Redwine ;

C C Mason ;

K R Reynolds ;

P M Clair ;

K C Gantz ;

T Y Zhang ;

A D Pomicter ;

I L Kraft ;

A D Bowler ;

K Johnson ;

M Mac Partlin ;

T O'Hare ;

M W Deininger .

Leukemia, 2015, 29 :2328-2337

[23] A Novel BCR-ABL1 Degrader, Ubx-362, Can Overcome Resistance By BCR-ABL1 Kinase Domain Mutations in Chronic Myeloid Leukemia [J].

Lim, Ye Seul ;

Jeong, Na-Rae ;

Yoo, Sun-Mi ;

Kim, Han Wool ;

Lee, Song Hee ;

Kim, Dong-Wook .

BLOOD, 2023, 142

[24] Mutational analysis of tyrosine kinase domain of BCR-ABL1 gene in chronic myeloid leukemia patients resistant to tyrosine kinase inhibitors [J].

Kihel, I. ;

Nachi, M. ;

Cayuela, J. ;

Bekadja, M. A. ;

Note, A. .

CLINICA CHIMICA ACTA, 2024, 558

[25] Mechanisms of Cardiovascular Toxicity of BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia [J].

Dakota Gustafson ;

Jason E. Fish ;

Jeffrey H. Lipton ;

Nazanin Aghel .

Current Hematologic Malignancy Reports, 2020, 15 :20-30

[26] Mechanisms of Cardiovascular Toxicity of BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia [J].

Gustafson, Dakota ;

Fish, Jason E. ;

Lipton, Jeffrey H. ;

Aghel, Nazanin .

CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2020, 15 (01) :20-30

[27] Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors [J].

Kim, Sung-Hyun ;

Menon, Hari ;

Jootar, Saengsuree ;

Saikia, Tapan ;

Kwak, Jae-Yong ;

Sohn, Sang-Kyun ;

Park, Joon Seong ;

Jeong, Seong Hyun ;

Kim, Hyeoung Joon ;

Kim, Yeo-Kyeoung ;

Oh, Suk Joong ;

Kim, Hawk ;

Zang, Dae Young ;

Chung, Joo Seop ;

Shin, Ho Jin ;

Do, Young Rok ;

Kim, Jeong-A ;

Kim, Dae-Young ;

Choi, Chul Won ;

Park, Sahee ;

Park, Hye Lin ;

Lee, Gong Yeal ;

Cho, Dae Jin ;

Shin, Jae Soo ;

Kim, Dong-Wook .

HAEMATOLOGICA, 2014, 99 (07) :1191-1196

[28] PREDICTIVE FACTORS FOR OUTCOME TO NOVEL BCR-ABL1 TYROSINE KINASE INHIBITORS IN IMATINIB FAILED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA [J].

Lee, S. E. ;

Choi, S. Y. ;

Kim, S. H. ;

Oh, Y. J. ;

Chae, M. J. ;

Song, H. Y. ;

Yoo, H. L. ;

Lee, M. Y. ;

Jang, E. J. ;

Jeong, K. H. ;

Lee, J. S. ;

Kim, D. W. .

HAEMATOLOGICA, 2014, 99 :336-336

[29] Brefeldin A Induces Apoptosis, Inhibits BCR-ABL Activation, and Triggers BCR-ABL Degradation in Chronic Myeloid Leukemia K562 Cells [J].

Zhang, Jin-Man ;

Wang, Cui-Fang ;

Wei, Mei-Yan ;

Dong, Hui ;

Gu, Yu-Cheng ;

Mo, Xiao-Mei ;

Shao, Chang-Lun ;

Liu, Ming .

ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2022, 22 (06) :1091-1101

[30] Long-term BCR-ABL1 Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia [J].

Pinilla-Ibarz, Javier ;

Sweet, Kendra ;

Emole, Josephine ;

Fradley, Michael .

ANTICANCER RESEARCH, 2015, 35 (12) :6355-6364

← 1 2 3 4 5 →